Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain.
OBJECTIVE
To determine the prevalence of CCR5-tropic HIV-1 among treatment-experienced patients in Spain.


METHODS
Epidemiologic, cross-sectional, and non-interventional study between January and June 2008 in HIV-1-infected patients in Spain.


METHODS
A total of 485 treatment-experienced patients from across Spainand with a plasma viral load of not greater-than1000 copies/mL were studied. Viral tropism, CD4+ cell count, plasma viral load, stage of disease, and current treatment strategies were determined. Univariate and multivariate logistic regression analyses were used to determine association of coreceptor use with patients' characteristics.


RESULTS
Coreceptor usage was determined by viral tropism assays: 290 (68.9%) patients had CCR5-tropic HIV-1 virus, and 131 (31.1%) had dual-tropic/mixed or CXCR4 virus variants. Mean CD4+ cell counts in the R5 group (319.4 cells/mm3) were higher than in the non-R5 group (237.9 cells/mm3) (p = .0005). There was an inverse relationship between CD4+ cell counts and plasma viral load, but regression analyses on covariates associated with CCR5 tropism showed that only a higher CD4+ cell number was significantly associated with CCR5 coreceptor usage.


CONCLUSIONS
The prevalence of CCR5-tropic HIV-1 among treatment-experienced patients in Spain is higher than previously found in other geographical settings. We did not find independent markers predictive of coreceptor usage other than a relationship with CD4+ levels.
Moreno
Hospital Ramón y Cajal, Madrid, Spain.
Clotet
Sarría
Ortega
Leal
Rodriguez-Arrondo
Sánchez-de la Rosa
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D003430:Cross-Sectional Studies; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D054884:Host-Pathogen Interactions; D006801:Humans; D015995:Prevalence; D019713:Receptors, CCR5 / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism; D013030:Spain / Q000453:epidemiology; D019562:Viral Load; D056189:Viral Tropism
D044966:Anti-Retroviral Agents; C527276:CXCR4 protein, human; D019713:Receptors, CCR5; D019718:Receptors, CXCR4